专利检索 ipc:"C07C317/46" 第 1 页

1.

发明公开
2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS 审中-公开

公开(公告)号：US20230150951A1

公开(公告)日：2023-05-18

申请号：US17909589

申请日：2021-03-08

申请人： OM PHARMA SA

发明人： Jacques BAUER , Olivier MARTIN

IPC分类号： C07D251/20 , C07C235/64 , C07C229/38 , C07C233/51 , C07C275/42 , C07C309/51 , C07C317/46 , C07D235/18

CPC分类号： C07D251/20 , C07C235/64 , C07C229/38 , C07C233/51 , C07C275/42 , C07C309/51 , C07C317/46 , C07D235/18

摘要： The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascular disorders, ophthalmologic disorders, fibrotic disorders, metabolic and gastrointestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein R1 is COOR4, (CH2)nCOOR4, SO3H, (CH2)nSO3H or CONH—R10; one of R2 and R3 is H and the other is R5.

2.

发明申请
SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF 有权

公开(公告)号：US20230002326A1

公开(公告)日：2023-01-05

申请号：US17582851

申请日：2022-01-24

申请人： University of Tennessee Research Foundation

发明人： Ramesh Narayanan , Duane D. Miller , Thamarai Ponnusamy , Dong-Jin Hwang , Yali He

IPC分类号： C07D231/16 , A61K31/4192 , A61K9/00 , A61K45/06 , C07D207/34 , A61K31/40 , C07D233/68 , A61K31/4164 , C07D207/06 , C07D295/15 , A61K31/5375 , C07D249/08 , A61K31/4196 , C07D213/84 , A61K31/44 , C07D239/74 , A61K31/517 , C07C255/60 , A61K31/277 , C07D401/12 , A61K31/4439 , C07D249/04 , A61K31/415 , C07C317/46 , C07D209/08

摘要： This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors. R-isomers, and non-hydroxylated and/or non-chiral propenamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

3.

发明授权
Processes for preparing 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile and for preparing sulindac 有权

公开(公告)号：US11161809B2

公开(公告)日：2021-11-02

申请号：US16854143

申请日：2020-04-21

申请人： HANGZHOU NORMAL UNIVERSITY , HANGZHOU LOOP BIOTECH CO., LTD

发明人： Weiming Xu , Wanmei Li , Lianzhi Tao , Pengfei Zhang , Hongyun Shen , Dongxiang Feng

IPC分类号： C07C315/02 , C07C253/22 , C07C317/46 , C07C255/35

摘要： The disclosure provides processes for preparing 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile and for preparing sulindac, relating to the field of medicine. The former comprises mixing 6-fluoro-2-methyl-1-indanone, cyanoacetic acid, a first organic solvent and an acetic acid-based catalyst to proceed with a first condensation reaction to give a first condensation reaction solution, which contains 5-fluoro-2-methyl-3-indanacetonitrile; and mixing the first condensation reaction solution, per se, with a base, a second organic solvent and 4-(methylthio)benzaldehyde to proceed with a second condensation reaction to give 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile. The process is a one-pot process without separation of 5-fluoro-2-methyl-3-indanacetonitrile from the solvent, shortening the synthetic route, simplifying the preparation process and improving the 5-fluoro-2-methyl-1-(4-methylthiobenzylidene)-3-indanacetonitrile yield.

4.

发明申请
SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF 审中-公开

公开(公告)号：US20200299243A1

公开(公告)日：2020-09-24

申请号：US16783161

申请日：2020-02-05

申请人： University of Tennessee Research Foundation

发明人： Ramesh NARAYANAN , Duane D. MILLER , Thamarai PONNUSAMY , Dong-Jin HWANG , Yali HE

IPC分类号： C07D231/16 , A61K31/4192 , A61K9/00 , A61K45/06 , C07D207/34 , A61K31/40 , C07D233/68 , A61K31/4164 , C07D207/06 , C07D295/15 , A61K31/5375 , C07D249/08 , A61K31/4196 , C07D213/84 , A61K31/44 , C07D239/74 , A61K31/517 , C07C255/60 , A61K31/277 , C07D401/12 , A61K31/4439 , C07D249/04 , A61K31/415 , C07C317/46 , C07D209/08

摘要： This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

5.

发明授权
Aryl ethers and uses thereof 有权

公开(公告)号：US10597366B2

公开(公告)日：2020-03-24

申请号：US16164653

申请日：2018-10-18

申请人： Peloton Therapeutics, Inc.

发明人： Darryl David Dixon , Jonas Grina , John A. Josey , James P. Rizzi , Stephen T. Schlachter , Eli M. Wallace , Bin Wang , Paul Wehn , Rui Xu , Hanbiao Yang

IPC分类号： C07B39/00 , C07C43/295 , A61K31/09 , C07D213/85 , C07C43/285 , C07C43/205 , C07C43/263 , C07C43/23 , C07C43/225 , A61K31/10 , C07C255/54 , C07C255/56 , C07C205/22 , C07C313/06 , C07C317/22 , C07C317/24 , C07C317/32 , C07C317/34 , C07C317/36 , C07C317/40 , C07C317/42 , C07C317/44 , C07C317/46 , C07C317/48 , C07C323/22 , C07C381/10 , C07D213/89 , C07D231/56 , C07D213/65 , C07C311/29 , A61K41/00 , A61P35/00 , C07C43/275 , C07C43/29

摘要： The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

6.

发明授权
Aryl ethers and uses thereof 有权

公开(公告)号：US10144711B2

公开(公告)日：2018-12-04

申请号：US15805390

申请日：2017-11-07

申请人： Peloton Therapeutics, Inc.

发明人： Darryl David Dixon , Jonas Grina , John A. Josey , James P. Rizzi , Stephen T. Schlachter , Eli M. Wallace , Bin Wang , Paul Wehn , Rui Xu , Hanbiao Yang

IPC分类号： A61P35/00 , A61K41/00 , A61K31/09 , C07C43/29 , C07C43/275 , C07D213/85 , C07C43/285 , C07C43/205 , C07C43/263 , C07C43/23 , C07C43/225 , A61K31/10 , C07C255/54 , C07C255/56 , C07C205/22 , C07C311/29 , C07C313/06 , C07C317/22 , C07C317/24 , C07C317/32 , C07C317/34 , C07C317/36 , C07C317/40 , C07C317/42 , C07C317/44 , C07C317/46 , C07C317/48 , C07C323/22 , C07C381/10 , C07D213/89 , C07D231/56 , C07D213/65

摘要： The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

7.

发明授权
Alkyl phenyl sulfide derivative and pest control agent 有权

公开(公告)号：US10023532B2

公开(公告)日：2018-07-17

申请号：US15091125

申请日：2016-04-05

申请人： KUMIAI CHEMICAL INDUSTRY CO., LTD.

发明人： Kei Domon , Keiji Toriyabe , Yutaka Ogawa , Junichiro Bessho , Kei Kawamoto , Akira Watanabe , Masaaki Komatsu , Takeshi Matsuda , Seisuke Ito

IPC分类号： C07C321/28 , C07C317/14 , A01N41/12 , C07D249/08 , C07D239/26 , C07C323/25 , C07D213/34 , C07D231/12 , C07D233/64 , C07D277/26 , C07C323/18 , A01N37/10 , A01N37/38 , C07C317/32 , C07C323/12 , C07C323/20 , C07C331/10 , A01N33/20 , A01N31/16 , C07C317/46 , C07C317/22 , A01N55/00 , A01N47/48 , A01N47/02 , A01N43/78 , A01N43/653 , A01N43/56 , A01N43/54 , A01N43/40 , A01N43/08 , A01N41/10 , A01N39/00 , A01N37/34 , A01N37/32 , C07C323/62 , A01N43/50

摘要： An alkyl phenyl sulfide derivative represented by the general formula [I] or an agriculturally acceptable salt thereof, and a pest control agent containing the derivative or the salt as an active ingredient. [in the above formula, R1 is, for example, a C1˜C6 alkyl group which is mono- or poly-substituted with halogen atom; R2 is, for example, a halogen atom or a C1˜C6 alkyl group; R3 is, for example, a hydrogen atom or a halogen atom; and R4 is, for example, a hydrogen atom or a C1˜C12 alkyl group.] The derivative or the salt has an excellent pest control effect.